Canaccord lowered the firm’s price target on iRhythm (IRTC) to $125 from $137 and keeps a Buy rating on the shares. The firm said they reported a solid Q3/24 and gave guidance in-line with expectations but they lowered their target to reflect both lower comp group multiples and slightly lower 2025 revenue due to the pushout of ZioMCT.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC: